Source: Pharma Circle Enterprise Announcement
MSD Revenue Reaches $60.1 Billion, with Blockbuster Drug K Making $25 BillionOn February 1, MSD announced its 2023 performance, with total revenue reaching $60.115 billion, a year-on-year increase of 1%. Among this, pharmaceutical business revenue was $53.583 billion, a year-on-year increase of 3%, and animal health business revenue was $5.625 billion, a year-on-year increase of 1%. Net profit was $395 million, a year-on-year decrease of 97%. From the financial statements, it can be seen that the reason for the decline in net profit was a significant increase in R&D investment.MSD's full-year net sales were $60.115 billion, with a cost of sales at $16.126 billion, resulting in a gross profit margin of 73.17%, which is approximately 3% higher than the same period last year. Market and general administrative expenses amounted to $10.504 billion, accounting for 17.47% of sales, an increase of 0.6% compared to the same period last year. R&D investment reached $30.531 billion, an increase of $17 billion from the same period last year. An R&D investment at the $30 billion level is unprecedented in the pharmaceutical industry, so MSD’s reputation for prioritizing R&D is well-deserved. Pfizer reported its full-year performance, showing a year-on-year decrease of 41%.Pfizer's Total Revenue in 2023 Reached $58.5 Billion, a Year-on-Year Decrease of 41%On January 30, Pfizer announced its Q4 and full-year 2023 financial results: Pfizer's total revenue for 2023 reached $58.5 billion, a year-over-year decrease of 41%, primarily due to the expected decline in revenue from the COVID-19 vaccine Comirnaty and the oral treatment Paxlovid; net profit was $2.119 billion, a year-over-year decrease of 93%. In Q4 2023, revenue was $14.2 billion, a year-over-year decrease of 42%, with a net loss of $3.369 billion in Q4 being the main reason for the sharp decline in annual performance. According to Pfizer’s official explanation, excluding the revenue from Comirnaty and Paxlovid, operational revenue increased by 7% driven by new product launches, new indications, and growth in inline products.It was reported that in January this year, Pfizer announced two rounds of layoffs, which are expected to affect more than 300 employees. Pfizer also cut three pipelines, namely the broad-spectrum antifungal candidate drug fosmangepix, the anti-tumor drug PF-07062119, and the B7H4/CD3 bispecific antibody PF-07260437.Semaglutide Annual Sales Exceed $200 BillionOn January 31, Novo Nordisk released its Q4 and full-year 2023 financial results. Total sales in 2023 reached DKK 232.261 billion, approximately USD 33.701 billion, representing a 31% increase year-over-year (at constant exchange rates).Among them, the total sales of Semaglutide in 2023 have reached approximately $21.158 billion. Specifically, the sales of the subcutaneous injection formulation Ozempic for diabetes treatment in 2023 were 95.718 billion Danish kroner (approximately $13.889 billion), an increase of 60%; the sales of the oral formulation Rybelsus were 18.75 billion Danish kroner (approximately $2.721 billion), a year-on-year increase of 66%; the sales of the weight loss drug Wegovy were 31.343 billion Danish kroner (approximately $4.548 billion), a year-on-year surge of 407%.Sanofi's Revenue Reached 43.1 Billion Euros in 2023, Dupixent Surpassed 11 Billion USD, Clopidogrel and Insulin Glargine Showed Counter-Trend Growth in ChinaOn February 1, French pharmaceutical giant Sanofi released its 2023 financial results, with annual revenue of 43.07 billion euros, a year-on-year increase of 0.2%, and net profit of 5.4 billion euros, a year-on-year decrease of 35.5%. In the fourth quarter, revenue was 10.919 billion US dollars, a year-on-year increase of 1.8%, while the fourth-quarter net profit was -555 million euros, a year-on-year decrease of 117.8%.It is worth mentioning that Sanofi's sales in China last year were 2.912 billion euros, a year-on-year increase of 0.4%, including 644 million euros in the fourth quarter, a year-on-year increase of 19.2%. The key drivers of growth were Dupixent (dupilumab), Toujeo (insulin glargine), and Plavix (clopidogrel). Interestingly, insulin glargine and clopidogrel have already been included in the centralized procurement list, yet these two products achieved counter-trend growth in the Chinese market. Moreover, the Chinese market has become a key factor driving the global sales growth of these two products.Novartis Achieves Annual Revenue of $45.44 Billion, Up 10% Year-on-Year, with Operating Profit of $9.776 BillionIn 2023, Novartis completed the spin-off of Sandoz, becoming a pure innovative pharmaceutical giant. According to the earnings report disclosed on January 31, Novartis achieved a full-year revenue of $45.44 billion, a year-on-year increase of 10%, with an operating profit of $9.776 billion, a year-on-year increase of 39%. The profit margin was 21.51%, showing a significant improvement compared to the same period last year.In terms of product revenue, Novartis' Entresto stood out remarkably, with full-year net sales reaching $6.036 billion, a 31% increase year-over-year; Cosentyx (secukinumab) grew by 5%, nearing the $5 billion milestone; the thrombopoietin receptor agonist PROMACTA (eltrombopag) achieved sales of $2.269 billion, marking a 10% year-over-year increase; Kesimpta (ofatumumab), used for treating multiple sclerosis, generated annual revenue of $2.171 billion, a 99% increase year-over-year; and the CDK4/6 inhibitor Kisqali (ribociclib) reported sales of $2.080 billion, reflecting a 15% year-over-year growth.Vaccines are GSK's brightest star, with annual revenue reaching £9.714 billion, a year-on-year increase of 14%.On January 31, British giant GSK announced its 2023 financial results, with full-year revenue of £30.328 billion, a year-on-year increase of 5%, and operating profit of £6.745 billion, a year-on-year increase of 10%. In the fourth quarter, revenue was £8.052 billion, a year-on-year increase of 15%, and operating profit was £673 million, a year-on-year decrease of 60%.In terms of product revenue, vaccines are GSK's brightest star, with annual revenue reaching £9.714 billion, a year-on-year increase of 14%. Revenue from Shingles (herpes zoster vaccine), Meningitis (meningococcal vaccine), and Arexvy (respiratory syncytial virus vaccine) reached £3.446 billion, £1.260 billion, and £1.238 billion respectively, with all three products showing rapid growth. In addition to vaccines, antiretroviral drugs, respiratory medicines, and anticancer drugs have also seen varying degrees of growth.Johnson & Johnson's 2023 Performance Released: Revenue of $85.2 Billion, Up 6.5% Year-over-YearJohnson & Johnson announced its 2023 financial results, with sales increasing by 6.5% year-over-year to reach $85.2 billion. However, net profit was only $13.3 billion, a year-over-year decrease of 18.6%. The fourth quarter showed relatively strong growth, with sales reaching $21.4 billion, a year-over-year increase of 7.3%, and net profit at $4.1 billion, a year-over-year increase of 28%.Because Johnson & Johnson divested its OTC and health care businesses last year, it now has only two major businesses remaining: innovative drugs and medical technology (devices and equipment). Among them, the annual revenue from innovative drugs was $54.8 billion, a year-on-year increase of 4.2%, while the revenue from the medical device business was $30.4 billion, a year-on-year increase of 10.8%.Follow the official account to get reliable and professional information and analysis content.
